Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?

Group 1 - AbCellera Biologics Inc. (ABCL) is currently ranked 2 (Buy) in the Zacks Rank, indicating a positive outlook for the stock [1] - The Zacks Consensus Estimate for ABCL's full-year earnings has increased by 4.4% over the past three months, reflecting improved analyst sentiment [2] - Year-to-date, ABCL has returned approximately 0.4%, outperforming the Medical sector average loss of about 1.1% [2] Group 2 - AbCellera Biologics Inc. is part of the Medical - Biomedical and Genetics industry, which ranks 78 in the Zacks Industry Rank, with an average loss of 11.6% this year [3] - Bionano Genomics, Inc. (BNGO), another stock in the Medical sector, has a year-to-date return of 5.8% and a Zacks Rank of 2 (Buy) [2] - Both AbCellera Biologics Inc. and Bionano Genomics, Inc. are expected to maintain solid performance in the Medical stocks space [3]